Insmed Incorporated
INSM
Rang in aandelen
#1101
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aandeelprijs
$96.65
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$21.11B
Verandering (1 dag)
-2.59%
Verandering (1 jaar)
-41.70%
Land
US
Handel Insmed Incorporated (INSM)
Categorie
Healthcare
Operationele marge voor Insmed Incorporated (INSM)
Operationele marge op October 2026 TTM: -71.86%
Volgens de meest recente financiële rapporten en aandelenkoers van Insmed Incorporated is de huidige operationele marge (TTM) -71.86%. Eind 2023 had het bedrijf een operationele marge van -232.51%.
Geschiedenis van de operationele marge van Insmed Incorporated van 2000 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | -71.86% | -70.24% |
| 2024 | -241.47% | 3.85% |
| 2023 | -232.51% | 19.32% |
| 2022 | -194.87% | -0.14% |
| 2021 | -195.14% | 20.96% |
| 2020 | -161.32% | -6.42% |
| 2019 | -172.38% | -94.48% |
| 2018 | -3,124.94% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -759.70% | 58.80% |
| 2013 | -478.39% | 0.00% |
| 2012 | 0.00% | -100.00% |
| 2011 | -1,397.31% | 1,095.10% |
| 2010 | -116.92% | 39.82% |
| 2009 | -83.62% | -32.12% |
| 2008 | -123.18% | -54.62% |
| 2007 | -271.47% | -95.05% |
| 2006 | -5,486.68% | -73.80% |
| 2005 | -20,941.98% | 4.61% |
| 2004 | -20,018.25% | 183.65% |
| 2003 | -7,057.33% | 272.65% |
| 2002 | -1,893.81% | -86.05% |
| 2001 | -13,576.35% | -90.01% |
| 2000 | -135,891.67% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -100.54% |
US
|
|
| -149.01% | -97.93% |
US
|
|
| 25.57% | -100.36% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.40% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.